Business Context and Reporting Period
Company: Galectin Therapeutics Inc. (GALT)
Filing Type: Form 8-K (Current Report)
Date of Report: August 13, 2024
Reporting Period: Three months ended June 30, 2024
This filing serves to announce the company's results of operations and financial condition for the second quarter of 2024, incorporating a press release issued on the same date.
Key Financial Metrics
The Form 8-K text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the body text. It directs readers to the attached press release for the business update and operational results.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes forward-looking statements regarding future financial performance, which are subject to risks and uncertainties.
- Risk Factors: Investors are directed to the "Risk Factors" section of the Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and subsequent SEC filings for detailed risk information.
- Safe Harbor: Statements are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
- Unusual Items: No unusual items are explicitly described in the filing text.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific Q2 2024 financial figures (revenue, net loss, cash position).
- Verify the company's cash runway and liquidity status as detailed in the press release.
- Consult the most recent Form 10-K and 10-Q filings for detailed risk factors and historical financial trends.
- Confirm any updates to the company's clinical development pipeline or business strategy mentioned in the business update.